Magnetic Resonance Spectroscopy suggests key differences in metastatic behaviour of medulloblastoma

Andrew Peet, Nigel Davies, Lee Ridley, Marie-Anne Brundler, Dimitris Kombogiorgas, S Lateef, Kalyan Natarajan, Spyridon Sgouros, L MacPherson, RG Grundy

Research output: Contribution to journalArticle

30 Citations (Scopus)


BACKGROUND: Metastatic medulloblastoma has a poorer prognosis than localised disease in part due to inherent properties of the tumour. 1H magnetic resonance spectroscopy (MRS) provides a powerful method for investigating tumour metabolism in vivo. METHODS: Magnetic resonance imaging and short echo time (Te 30 ms) single voxel MRS were performed on the primary tumour of 16 children with medulloblastoma prior to surgical resection. Tumour volumes were calculated using a segmentation technique and the MRS was analysed using LCModel. RESULTS: Patients with metastatic disease had primary tumours which were smaller (p=0.01), had higher levels of total choline (p=0.03) and lower levels of mobile lipids (p=0.04). CONCLUSION: Metastatic medulloblastomas have metabolite profiles indicative of increased cell growth and decreased cell death compared with localised tumours reflecting intrinsic differences in underlying biology. Localised tumours with an MRS metabolite profile similar to those with metastatic disease may be at increased risk of metastatic relapse.
Original languageEnglish
Pages (from-to)1037-1044
Number of pages8
JournalEuropean Journal of Cancer
Issue number6
Publication statusPublished - 1 Apr 2007


Dive into the research topics of 'Magnetic Resonance Spectroscopy suggests key differences in metastatic behaviour of medulloblastoma'. Together they form a unique fingerprint.

Cite this